Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TARO-GLICLAZIDE MR - Health Canada Drug Approval Details

Approvals/Health Canada/TARO-GLICLAZIDE MR

Authorized

STANDARD

TARO-GLICLAZIDE MR

sun pharma canada inc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: bc8968b337a4fdf0
Company: sun pharma canada inc
Type: Standard

Approval Details

Approval Id: bc8968b337a4fdf0
Drug Approval Canada Name: TARO-GLICLAZIDE MR
Product Name: TARO-GLICLAZIDE MR
Status: Marketed
Status Date: 2021-02-22
Original Market Date: 2018-04-03
Din: 02463571
Drug Class: Human
Dosage Form: Tablet (Extended-Release)
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 68:20.20
Atc Original: A10BB09 GLICLAZIDE
Atc Name: a 10 bb 09
Aig Number: 0119934002
Company Name: sun pharma canada inc
Company Address: 126 East Drive, Brampton, Ontario, Canada, L6T 1C1

Active Ingredients

GLICLAZIDE

30 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

bc8968b337a4fdf0

Type

Standard

Back to Health Canada Approvals